Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Angiodynamics (ANGO) over the last 17 years, with Q4 2025 value amounting to $2.9 million.

  • Angiodynamics' Share-based Compensation rose 1435.92% to $2.9 million in Q4 2025 from the same period last year, while for Nov 2025 it was $11.4 million, marking a year-over-year increase of 1131.73%. This contributed to the annual value of $9.8 million for FY2025, which is 718.97% down from last year.
  • Latest data reveals that Angiodynamics reported Share-based Compensation of $2.9 million as of Q4 2025, which was up 1435.92% from $4.5 million recorded in Q3 2025.
  • Angiodynamics' 5-year Share-based Compensation high stood at $4.5 million for Q3 2025, and its period low was $1.6 million during Q2 2025.
  • Over the past 5 years, Angiodynamics' median Share-based Compensation value was $2.6 million (recorded in 2024), while the average stood at $2.7 million.
  • Per our database at Business Quant, Angiodynamics' Share-based Compensation tumbled by 4397.01% in 2023 and then skyrocketed by 4486.97% in 2024.
  • Angiodynamics' Share-based Compensation (Quarter) stood at $3.0 million in 2021, then rose by 11.37% to $3.4 million in 2022, then plummeted by 43.97% to $1.9 million in 2023, then soared by 34.68% to $2.5 million in 2024, then rose by 14.36% to $2.9 million in 2025.
  • Its last three reported values are $2.9 million in Q4 2025, $4.5 million for Q3 2025, and $1.6 million during Q2 2025.